ULI262

The problem

No drug to prevent bowel cancer

Curileum discovered and is developing a novel, oral small molecule drug that addresses the root cause of bowel cancer: mutations leading to abnormal cell production forming polyps and progressing to cancer.

Bowel cancer is one of the most common and deadly cancers worldwide. Current strategies for bowel cancer prevention rely on periodic colonoscopies and surgical removal of polyps, which are costly, invasive and burdensome for patients. Despite screening programmes, many high-risk individuals still develop cancer.

Contact us to discuss potential investment opportunities

Get in touch

The problem

It starts with a polyp, no effective medical treatment

All bowel cancer develops from polyps Polyps are overgrowths of gut mucosa that can develop mutations leading to cancer.
Surveillance is inefficient and costly Bowel screening programs use a home FIT test every two years after age 60, with limited colonoscopy uptake and costs ranging from $1,000 to $3,000.
No drug to reduce polyps and risk of cancer Standard care involves surveillance and polyp removal, but over 10% of polyps are missed and more than 10% of colorectal cancer cases relapse.

Our solution

ULI262- a first-in-class small molecule drug

Our first-in-class small molecule drug, ULI262, addresses these large, unmet needs in bowel cancer prevention, targeting FAP patients, high-risk individuals identified in screening programmes, and post-cancer treatment prone to relapse.

By re-directing precancerous cells toward normal tissue, ULI262 may prevent progression to cancer – offering the first scalable, non-invasive pharmacological solution for bowel cancer prevention. 

Curileum is currently preparing for first-in-human clinical studies to treat patients with FAP. We expect the FDA will grant Orphan drug designation for the treatment of FAP, helping to expedite the clinical trial process and accelerate the timeline to treating patients in urgent need. 

Why ULI262

Properties and advantages of ULI262

Potent and safe ULI262 has been shown to be 100x more potent in vitro than other drugs.
Dual action properties Dual action properties distinguish it from other agents – it redirects precancerous to healthy cell production and has powerful anti-inflammatory properties.
Wide potential therapeutic range in vitro activity shown over a 4-log range.
Delivered as oral pill Can be delivered as an oral pill making it a highly desirable treatment for patients and a cost-effective solution for healthcare systems.
Non-surgical treatment For patients with FAP, ULI262 offers the first potential non-surgical treatment.